Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

131 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-05-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will provide data (variations in ventricular size and function) that are essential to designing and conducting clinical trials. In addition, the study will evaluate intra- and inter-study variability seen in echocardiography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pathophysiology of Dilated Cardiomyopathy

NCT02001961

Dilated Cardiomyopathy

WITHDRAWN

Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

NCT01873976

Dilated Cardiomyopathy Hypertrophic Cardiomyopathy

UNKNOWN

Single Ventricle Outcome

NCT00308217

Heart Disease, Congenital Single Ventricle Hypoplastic Left Heart Syndrome

COMPLETED

PRecIsion Medicine in CardiomyopathY

NCT04036799

Hypertrophic Cardiomyopathy Sudden Cardiac Death

ACTIVE_NOT_RECRUITING

Pediatric Cardiomyopathy Mutation Analysis

NCT02432092

Cardiomyopathies Dilated Cardiomyopathy Hypertrophic Cardiomyopathy +3 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

Cardiomyopathy is an important cause of chronic disability and death in pediatric patients and currently accounts for approximately 50% of cardiac transplants performed during childhood. Left ventricular (LV) size and function are important independent predictors of outcome, and echocardiography is the primary way to assess ventricular function in children. Although there is extensive experience with this technology, data are limited on how ventricular function changes over time in children, which is a major impediment to conducting controlled trials of therapy in children.

This study has been approved by the Institutional Review Boards/Research Ethics Boards of all participating clinical centers:

Hospital for Sick Children, Toronto, Canada

Children's Hospital Boston, Boston, MA

Columbia College of Physicians and Surgeons, New York, NY

Children's Hospital of Philadelphia, Philadelphia, PA

Duke University Medical Center, Durham, NC

Brody School of Medicine at East Carolina University, Greenville, NC

Wake Forest Baptist Medical Center, Winston Salem, NC

Medical University of South Carolina, Charleston, SC

Primary Children's Medical Center, Salt Lake City, UT

Washington University, St. Louis, MO

DESIGN NARRATIVE:

This observational study will prospectively evaluate pediatric patients with dilated cardiomyopathy who are undergoing clinically indicated echocardiographic evaluation of LV function. Patients who undergo at least two echocardiograms 3 to 18 months apart will have their studies performed by the same ultrasonographer. All studies will be sent to the core laboratory for evaluation of variability in LV mass, volume, and ejection fraction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiomyopathy, Dilated

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Less than 22 years of age
* Any race
* Diagnosis of dilated cardiomyopathy
* LV and diastolic diameter greater than 5.5 cm (or z-score for BSA greater than 2) on the primary image acquisition from the first study echocardiogram
* LV ejection fraction less than 50% (or z-score for age less than -2) or shortening fraction less than 28% (or z-score for age less than -2) as measured on the primary image acquisition from the first study echocardiogram
* Disease onset greater than 2 months prior to screening
* Anticipated to undergo repeat evaluation at the same institution at least 3 months but not more than 13 months later
* Informed consent of parent(s) or legal guardian and assent of subject if required

Exclusion Criteria

* Hypertrophic cardiomyopathy
* Restrictive cardiomyopathy
* Myocardial noncompaction (LV hypertrabeculation); patient is eligible for the study as long as the echocardiogram performed at the time of screening has no evidence of myocardial noncompaction
* Ventricular paced rhythm
* Atrial or ventricular ectopy at ratio greater than 1:4
* Suspected acute myocarditis
* Tachycardia-induced cardiomyopathy
* Congenital heart disease (repaired or unrepaired)
* Currently on intravenous inotropic support
* Current left ventricular assist device (LVAD) or extracorporeal membrane oxygenation (ECMO)
* Heart transplant waiting list status of 1A or 1B
* Co-morbid condition that precludes the ability to successfully obtain an echocardiogram according to the specifications of the study protocol

Maximum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No